echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Almiral launches Seysara tablets in the U.S. for treatment of common acne patients

    Almiral launches Seysara tablets in the U.S. for treatment of common acne patients

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, Spain's Almiralcompany(http:// announcedthe launch of Seysara tablets in the United States for treatment of patients with moderate to severe non-nodactive inflammatory acne at age 9 and olderin the United States, Seysara was approved in early October 2018, becoming the first oral antibioticproduct designed for dermatology in the past 40 years,(http://, which will provide an innovative treatment option for patients with moderate to severe acneabout Seysara
    Seysara is a pioneering (first-in-class), narrow-spectrum tetracycline-derived antibiotic, which has anti-inflammatory properties and is taken daily orally, can be taken with or without food, and has been shown in clinical studies to achieve a statistically significant improvement in dermatital lesions within 3 weeks of starting the drug, with good safety and toleranceSeysara was discovered by the antibiotic company Paratek and granted the exclusive rights to the product to Aer Insp, while retaining the rights to develop and commercialize the product in other parts of the worldin early August, Almirall announced a $550 million acquisition of five products from the http://dermatology division of El-Sin in the United
    States, including four mature brands, Aczone ®, T®aztenaroe, Azelex® and Cordrasan®, as well as the first-of-its-kind innovative four-ring-derived antibiotic, SeysaraUnder the previous agreement between Paratek and ElJian, This time Seysara was approved by the u.SFDA(http:// , Paratek will receive a $12 million milestone and be entitled to tiered royalties related to Seysara's net sales in the U.S market safety it is important to note that the Seysara taboo is used in patients with allergies to the http:// of the drug , which can cause permanent discoloration during dental development Seysara should be deactivated in the event of clottalysis-associated diarrhea (antibiotic-related colitis) or intracranial hypertension Central nervous system side effects, the most common including mild dizziness or dizziness, have been reported in tetracycline therapy In clinical studies, the most common adverse reactions of Seysara (incidence of 1%) were nausea
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.